Retatrutide (GLP-3s)

Editors’ Note: We’re excited to share our website with you! It features a healthspan-focused job board, an archive of past newsletters, a growing dictionary of terms we’ve highlighted in previous editions and more to come!

Visit us at: https://stacked-health.com/

Or copy and paste this link to others: {{rp_refer_url}}

If you've been reading metabolic health Twitter like us, one word keeps appearing: reta.

Retatrutide is Eli Lilly's investigational obesity drug. In December 2025, it produced the most extreme weight loss numbers ever seen in a Phase 3 trial. Average participants lost 71.2 pounds, or 28.7% of their body weight, over 68 weeks. To put that in context: Ozempic (semaglutide) tops out around 15%. Zepbound (tirzepatide) lands around 22.5%. Retatrutide blew past both, and the weight loss curve hadn't plateaued when the trial ended.

It's not approved. It won't be approved for at least another 18 to 24 months. However, the market always finds a way, and people are already sourcing it via Telegram and compounding pharmacies operating in legal grey zones.

Here's what makes it different from everything that came before.

One lever, two levers, three levers

The simplest way to understand retatrutide is as the third generation of weight loss drugs. Each generation adds a hormone receptor to the molecule.

Semaglutide (Ozempic, Wegovy) is a single agonist. It activates one receptor: GLP-1. GLP-1 is the hormone your gut releases after a meal that tells your brain you're full, slows down gastric emptying, and triggers insulin release. Hitting this one receptor produces the appetite suppression that powers most of Ozempic's effect.

Tirzepatide (Mounjaro, Zepbound) is a dual agonist. It hits GLP-1 plus GIP. GIP is a related gut hormone that amplifies insulin response and, somewhat counterintuitively, appears to reduce the nausea side effects of GLP-1 agonism. Adding GIP turned out to be a force multiplier, which is why tirzepatide produces noticeably more weight loss than semaglutide.

Retatrutide is a triple agonist. It hits GLP-1, GIP, and glucagon in a single 39-amino-acid molecule. That third receptor is where things change.

Why adding glucagon is a big deal

GLP-1 and GIP both work primarily on the intake side of the energy balance equation. They make you eat less.

Glucagon is different. Glucagon is the hormone that tells your liver to release stored glucose and burn fat for energy. It increases your resting metabolic rate. It works on the output side of the equation.

Historically, this is also why adding glucagon to a weight loss drug seemed insane. Glucagon is the body's "anti-insulin" hormone. Activating it in isolation would raise blood sugar, which is the opposite of what you want in a diabetes or obesity drug.

The trick of retatrutide is that the GLP-1 and GIP components counterbalance glucagon's blood sugar effects. You get the metabolic rate boost without the hyperglycemia. In TRANSCEND-T2D-1, the Phase 3 type 2 diabetes trial that read out in March 2026, retatrutide actually improved glycemic control while delivering weight loss.

So instead of one lever (appetite) or two (appetite + insulin signaling), retatrutide pulls three: it makes you eat less, processes the food better, and burns more calories at rest. That's why the weight loss numbers are so much larger.

The pipeline is much bigger than weight loss

Eli Lilly isn't just running retatrutide as an obesity drug. The TRIUMPH program is testing it across knee osteoarthritis, obstructive sleep apnea, chronic low back pain, metabolic dysfunction–associated steatotic liver disease (MASH), and cardiovascular/renal outcomes.

Reta will go to market as a metabolic platform, not a weight loss product. If two or three of those indications hit, retatrutide could become the most prescribed drug in America by the early 2030s.

Reta is already on the grey market

We covered the China-to-consumer peptide pipeline in our Peptides 101 piece. Retatrutide is now firmly inside it.

Vials labeled "for research use only" sell for $150 to $500 per month. Some U.S. compounding pharmacies have started offering it with telehealth prescriptions, though the legal basis is shaky: compounding generally requires the underlying drug to be FDA-approved or on the FDA's bulk substances list, and retatrutide is neither. The FDA has not yet taken enforcement action.

The published 28.7% weight loss figure assumes pharmaceutical-grade molecule at a precisely titrated dose under medical supervision. None of those conditions apply to a research vial of unverified concentration mixed on someone's kitchen counter. The clinical data tells you nothing about what to expect from grey market reta, and there's no pharmacovigilance system catching adverse events.

Why you should care

Retatrutide is the first obesity drug that has a credible shot at breaking the 30% weight loss ceiling without surgery. That number is roughly the threshold at which medical weight loss becomes competitive with bariatric procedures.

Single agonists were appetite suppression. Dual agonists were appetite plus metabolism. Triple agonists are appetite plus metabolism plus energy expenditure.

The science is moving faster than the regulatory pathway as usual. The grey market is moving faster than both.

Or copy and paste this link to others: {{rp_refer_url}}

Current Referral Count: {{rp_num_referrals}}